基本信息
浏览量:250
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
My early work was focusing on the biology and function of small nuclear RNAs and later I was heavily involved in lung cancer gene therapy and functional studies of oncogenes. For the past decade, I have been involved in studies investigating the role of biomarkers in improving cancer risk and outcome prediction. I also have a keen interest in genome-wide molecular profiling (SNP array CGH, mRNA, microRNA, and methylation array) of somatic tissues, including premalignant and malignant tissues, to identify biomarkers of diagnosis and prognosis of cancer. My current major research projects are the role of epigenetics (e.g., DNA methylation) in predicting aggressive prostate cancer and racial disparity of prostate cancer. I have an ongoing CPRIT grant to study DNA methylation in peripheral blood as biomarkers of aggressive prostate cancer. We are extending DNA methylation research to address racial disparity issue in African Americans who have a greater incidence of prostate cancer and higher mortality. DNA methylation sits at the interface between genetics and environment. Age, obesity, smoking and ethnicity, established risk and prognostic factors for PCa, have major impact on DNA methylation. DNA methylation in peripheral blood leukocytes (PBLs) may also infer the state of immune system. Our hypothesis is that PCa in AA men exhibit racial specific PBL epigenome associated with aggressive PCa. A secondary hypothesis is that AA patients have a distinct leukocyte composition that may indicate weaker cellular immunity and thus more aggressive disease. Another cancer site that my lab is working on is soft tissue sarcoma (STS): to identify genetic and phenotypic susceptibility factors for STS. In addition, we are also working on functional studies of genetic variations, DNA methylation and microRNAs in the context of cancer risk and outcomes.
My major research interests are to identify genetic susceptibility genes to cancer development, intermediate biomarkers of cancer risk and outcomes, and circulating biomarkers for cancer risk and early detection. My current major research focuses are to investigate the role of epigenetics (e.g., DNA methylation) in predicting aggressive prostate cancer and racial disparity of prostate cancer and to identify circulating methylated DAN as biomarkers for early detection and prognosis using whole genome methylation array and bisulfite next generation sequencing technology. I have an ongoing CPRIT grant to study DNA methylation in peripheral blood as biomarkers of aggressive prostate cancer. We are extending DNA methylation research to address racial disparity issue in African Americans who have a greater incidence of prostate cancer and higher mortality. DNA methylation sits at the interface between genetics and environment. Age, obesity, smoking and ethnicity, established risk and prognostic factors for PCa, have major impact on DNA methylation. DNA methylation in peripheral blood leukocytes (PBLs) may also infer the status of immune system. Our hypothesis is that PCa in AA men exhibit racial specific PBL epigenome associated with aggressive PCa. A secondary hypothesis is that AA patients have a distinct leukocyte composition that may indicate weaker cellular immunity and thus more aggressive disease. In addition, we are also working on functional studies of genetic variations, DNA methylation and microRNAs in the context of cancer risk and outcomes.
My major research interests are to identify genetic susceptibility genes to cancer development, intermediate biomarkers of cancer risk and outcomes, and circulating biomarkers for cancer risk and early detection. My current major research focuses are to investigate the role of epigenetics (e.g., DNA methylation) in predicting aggressive prostate cancer and racial disparity of prostate cancer and to identify circulating methylated DAN as biomarkers for early detection and prognosis using whole genome methylation array and bisulfite next generation sequencing technology. I have an ongoing CPRIT grant to study DNA methylation in peripheral blood as biomarkers of aggressive prostate cancer. We are extending DNA methylation research to address racial disparity issue in African Americans who have a greater incidence of prostate cancer and higher mortality. DNA methylation sits at the interface between genetics and environment. Age, obesity, smoking and ethnicity, established risk and prognostic factors for PCa, have major impact on DNA methylation. DNA methylation in peripheral blood leukocytes (PBLs) may also infer the status of immune system. Our hypothesis is that PCa in AA men exhibit racial specific PBL epigenome associated with aggressive PCa. A secondary hypothesis is that AA patients have a distinct leukocyte composition that may indicate weaker cellular immunity and thus more aggressive disease. In addition, we are also working on functional studies of genetic variations, DNA methylation and microRNAs in the context of cancer risk and outcomes.
研究兴趣
论文共 351 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer genomics & proteomicsno. 2 (2024): 144-157
Nature communicationsno. 1 (2024): 3718-3718
crossref(2024)
Mark P Purdue,Diptavo Dutta,Mitchell J Machiela,Bryan R Gorman,Timothy Winter, Dayne Okuhara, Sara Cleland,Aida Ferreiro-Iglesias,Paul Scheet,Aoxing Liu, Chao Wu,Samuel O Antwi,
The Prostate/The prostateno. 7 (2024): 694-705
HEPATOLOGY (2024)
NATURE GENETICSno. 5 (2024): 819-826
Hepatology (Baltimore, Md.)no. 1 (2024): 87-101
Prostate cancer and prostatic diseasesno. 2 (2024): 339-347
加载更多
作者统计
#Papers: 347
#Citation: 15151
H-Index: 73
G-Index: 115
Sociability: 8
Diversity: 0
Activity: 3
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn